INDP
Indaptus Therapeutics, Inc.
$2.10
-42.62%
$237.8M
No data for this timeframe.
Vol
Market Cap$237.8M
Cap SizeMicro Cap
Inst. Holders1 funds
Inst. Value$73.00
Inst. Activity0 buys / 2 sells
Insider Activity0B / 2S
SEC Reports4
Recent Activity
May 15, 2026
SEC
Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period with only $1.5M in
8-K — Impact 7/10
May 15, 2026
SEC
Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share)
PRESS-RELEASE — Impact 8/10
Apr 23, 2026
SEC
Indaptus Therapeutics appointed two new independent directors, Tim Ruan and Dr. Yi Zhang, while Matthew McMurdo resigned
8-K — Impact 3/10
Mar 23, 2026
Insider
Lazar David E. sold 700,000 shares
Director @ $0.00 ($0.00)
Mar 23, 2026
Insider
Lazar David E. sold 196,800 shares
Director @ $0.00 ($0.00)
Feb 26, 2026
Insider
Jabbour Jerome D sold 25,000 shares
Director @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — EXIT
0 shares ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — EXIT
0 shares ($0.00)
Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$10.00 (Nov 2024)
Current $3.43
Low $10.00
Median $10.00
High $10.00
1 analysts
$10.00
$10.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 13, 2024 | Maxim Group | MAINTAIN | Buy → Buy |
| Oct 16, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jun 17, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 15, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Sep 20, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Latest Reports
BEARISH
8-K
7/10
Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period with only $1.5M in
May 15, 2026
BEARISH
PRESS-RELEASE
8/10
Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share)
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $73.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 23, 2026 | Lazar David | SELL | $0.00 |
| Mar 23, 2026 | Lazar David | SELL | $0.00 |
| Feb 26, 2026 | Jabbour Jerome | A | $0.00 |
| Feb 11, 2026 | Meckler Jeffrey | D | $0.00 |
| Feb 11, 2026 | Meckler Jeffrey | A | $0.00 |
1 institutional holders with $73.00 total value (25 shares) as of 2025-Q4. Top holders: BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 25 | $73.00 | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | EXIT | 256,265 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 28,500 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 2,523 | 87 | -96.6% | $49.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 522 | 2,523 | +383.3% | $2.1K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 15,390 | 0 | -100.0% | $0.00 | 2024-Q4 |
3 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Lazar David E. | Director | SELL | 700,000 | $0.00 | $0.00 |
| Mar 23, 2026 | Lazar David E. | Director | SELL | 196,800 | $0.00 | $0.00 |
| Feb 26, 2026 | Jabbour Jerome D | Director | A | 25,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | D | 3,033 | $0.00 | $0.00 |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | A | 3,033 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.3/10.
BEARISH
8-K
7/10
Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period
May 15, 2026
BEARISH
PRESS-RELEASE
8/10
Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from
May 15, 2026
NEUTRAL
8-K
3/10
Indaptus Therapeutics appointed two new independent directors, Tim Ruan and Dr. Yi Zhang, while Matt
Apr 23, 2026
NEUTRAL
8-K
3/10
Indaptus Therapeutics announced the resignation of CFO Nir Sassi and the immediate appointment of Yu
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$10.00 mean target (Nov 2024)
$10.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $3.43 |
| Target Low | $10.00 |
| Target Mean | $10.00 |
| Target Median | $10.00 |
| Target High | $10.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 13, 2024 | Maxim Group | MAINTAIN | Buy | Buy |
| Oct 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 17, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 20, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 11, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 8, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 4, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 20, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 8, 2023 | HC Wainwright & Co. | REITERATE | — | Overweight |
| Feb 8, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Oct 19, 2021 | Maxim Group | UPGRADE | Hold | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: INDP — 61.7% short (0.4M / 0.6M)
Short: 368,057 | Exempt: 59,628 | TRF Vol: 596,257 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: INDP — 59.4% short (0.3M / 0.5M)
Short: 321,355 | Exempt: 60,723 | TRF Vol: 541,331 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="left">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stag
May 12, 2026
earnings_calendar
INDP Q1 2026 Earnings Scheduled — 2026-05-12
Mar 10, 2026
earnings_calendar
INDP Q4 2025 Earnings After Market Close — 2026-03-10